| Bioactivity | MK-0941 free base is an orally active glucokinase activator, with EC50s of 240 and 65 nM for recombinant human glucokinase in the presence of 2.5 and 10 mM glucose, respectively. MK-0941 free base exhibits strong glucose-lowering activity and is a potential therapeutic agent for treatment of type 2 diabetes[1][2]. |
| Target | Glucokinase. |
| In Vivo | MK-0941 free base (3 or 10 mg/kg, sing oral dose) treatment reduced blood glucose significantly in db/db diabetic mouse[1]. Animal Model: |
| Name | MK-0941 free base |
| CAS | 752240-01-0 |
| Formula | C21H24N4O6S |
| Molar Mass | 460.50 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Eiki J, et al. Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs. Mol Pharmacol. 2011 Dec;80(6):1156-65. [2]. Meininger GE, et al. Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care. 2011 Dec;34(12):2560-6. |
MK-0941 free base
CAS: 752240-01-0 F: C21H24N4O6S W: 460.50
MK-0941 free base is an orally active glucokinase activator, with EC50s of 240 and 65 nM for recombinant human glucokina
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.